Valion Bio announces preferred stock and warrant sales totaling $4.77 million

Valion Bio, Inc. (VBIO) has announced the sale of $4.77 million worth of Series B and Series C Non-Voting Convertible Preferred Stock and related warrants. This capital raise comes as the company's stock trades at $0.84 per share, with a market capitalization of $750,000, down nearly 99% over the past year. Valion Bio is currently facing financial challenges, with a high debt-to-equity ratio of 4.1 and a significant burn rate.

The company's shares are considered undervalued, according to InvestingPro Tips. The transactions were executed in private placements exempt from registration under the Securities Act of 1933 and/or Rule 506(b).

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.